Evidence map›Paper›PMID 35208174›Full record

ArticleMetabolites2022

Analogues of Natural Chalcones as Efficient Inhibitors of AKR1C3.

Gabriele Möller, Veronika Temml, Antonio Cala Peralta, Océane Gruet, Pascal Richomme, Denis Séraphin, Guillaume Viault, Luisa Kraus, Petra Huber-Cantonati, Elisabeth Schopfhauser and 5 more

Open access · goldAbstract read
In one paragraph

Article in Metabolites, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. The geroprotective potential of chalcones.Nature communications · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Two Important Anticancer Mechanisms of Natural and Synthetic Chalcones.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 3 countries.

Gabriele MöllerInstitute for Diabetes and Cancer, Helmholtz Center Munich, German Research Center for Environmental Health, 85764 Neuherberg, Germany.ORCID 0000-0002-2730-1351
Veronika TemmlDepartment of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.
Antonio Cala PeraltaUniversity of Angers, SONAS, SFR QUASAV, F-49000 Angers, France.ORCID 0000-0001-5714-4556
Océane GruetUniversity of Angers, SONAS, SFR QUASAV, F-49000 Angers, France.
Pascal RichommeUniversity of Angers, SONAS, SFR QUASAV, F-49000 Angers, France.
Denis SéraphinUniversity of Angers, SONAS, SFR QUASAV, F-49000 Angers, France.ORCID 0000-0002-0509-5788
Guillaume ViaultUniversity of Angers, SONAS, SFR QUASAV, F-49000 Angers, France.ORCID 0000-0002-7359-7595
Luisa KrausInstitute of Pharmacy, Pharmaceutical Biology and Clinical Pharmacy, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.
Petra Huber-CantonatiInstitute of Pharmacy, Pharmaceutical Biology and Clinical Pharmacy, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.
Elisabeth SchopfhauserDepartment of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.
Johanna PachmayrInstitute of Pharmacy, Pharmaceutical Biology and Clinical Pharmacy, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.
Janina TokarzInstitute for Diabetes and Cancer, Helmholtz Center Munich, German Research Center for Environmental Health, 85764 Neuherberg, Germany.ORCID 0000-0003-4344-4149
Daniela SchusterDepartment of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.ORCID 0000-0002-9933-8938
Jean-Jacques HelesbeuxUniversity of Angers, SONAS, SFR QUASAV, F-49000 Angers, France.ORCID 0000-0002-1894-8911
Kenneth Allen DyarInstitute for Diabetes and Cancer, Helmholtz Center Munich, German Research Center for Environmental Health, 85764 Neuherberg, Germany.ORCID 0000-0002-9010-8757
Paracelsus Medical University · ATUniversité d'Angers · FRHelmholtz Zentrum München · DE

Funding

Austrian Science Fund FWF T 942
6 · The paper itself

Abstract

Naturally occurring substances are valuable resources for drug development. In this respect, chalcones are known to be antiproliferative agents against prostate cancer cell lines through various mechanisms or targets. Based on the literature and preliminary results, we aimed to study and optimise the efficiency of a series of chalcones to inhibit androgen-converting AKR1C3, known to promote prostate cancer. A total of 12 chalcones with different substitution patterns were synthesised. Structure-activity relationships associated with these modifications on AKR1C3 inhibition were analysed by performing enzymatic assays and docking simulations. In addition, the selectivity and cytotoxicity of the compounds were assessed. In enzymatic assays, C-6' hydroxylated derivatives were more active than C-6' methoxylated derivatives. In contrast, C-4 methylation increased activity over C-4 hydroxylation. Docking results supported these findings with the most active compounds fitting nicely in the binding site and exhibiting strong interactions with key amino acid residues. The most effective inhibitors were not cytotoxic for HEK293T cells and selective for 17β-hydroxysteroid dehydrogenases not primarily involved in steroid hormone metabolism. Nevertheless, they inhibited several enzymes of the steroid metabolism pathways. Favourable substitutions that enhanced AKR1C3 inhibition of chalcones were identified. This study paves the way to further develop compounds from this series or related flavonoids with improved inhibitory activity against AKR1C3.

Indexed as

17β-hydroxysteroid dehydrogenase3α-hydroxysteroid dehydrogenaseAKR1C3aldo-keto reductasecancerchalconestructure-activity relationship

Identifiers

PMID35208174
PMCPMC8876231
OpenAlexW4206976188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.